Depletion of Adipose Stroma-Like Cancer-Associated Fibroblasts Potentiates Pancreatic Cancer Immunotherapy

Joseph Rupert1, Alexes Daquinag1, Yongmei Yu1

  • 1Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for the Prevention of Disease, McGovern Medical School, Houston, Texas.

PubMed

Insights

Targeting adipose stromal cell-like cancer-associated fibroblasts (CAFs) with D-CAN peptide enhances immune checkpoint blockade therapy effectiveness in pancreatic cancer models. This approach may improve treatment outcomes for patients resistant to current immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Immune checkpoint blockade (ICB) therapy is ineffective in pancreatic cancer.
  • Cancer-associated fibroblasts (CAFs) influence tumor progression and therapy resistance.
  • Subpopulations of CAFs, including Pdgfrb+ CAFs and adipose stromal cell (ASC)-like CAFs, have distinct roles.

Purpose of the Study:

  • To investigate the roles of Pdgfrb+ CAFs and ASC-like CAFs in pancreatic ductal adenocarcinoma progression and therapy resistance.
  • To evaluate the therapeutic potential of targeting ASC-like CAFs, alone and in combination with ICB.

Main Methods:

  • Analysis of CAFs in mouse models of pancreatic ductal adenocarcinoma.
  • Ablation of Pdgfrb+ cells and induction of apoptosis in ASC-like CAFs using peptide D-CAN.
  • Single-cell RNA sequencing to assess cellular composition and markers.
  • Combination therapy with D-CAN and anti-PDL1 (aPDL1) antibody.

Main Results:

  • Ablation of Pdgfrb+ CAFs suppressed tumor growth but increased liver metastasis.
  • D-CAN treatment reduced tumor growth and extracellular matrix deposition but promoted metastasis.
  • Depletion of either CAF subpopulation altered tumor microenvironment, affecting endothelial cells and cancer cells.
  • Depletion of ASC-like CAFs increased cytotoxic T-lymphocyte and B-lymphocyte infiltration.
  • Combination of D-CAN and aPDL1 showed enhanced tumor suppression and reduced liver metastasis compared to aPDL1 alone.

Conclusions:

  • Targeting ASC-like CAFs with D-CAN can potentiate the anti-tumor effects of immune checkpoint blockade in pancreatic cancer.
  • Distinct CAF subpopulations have opposing effects on tumor progression and metastasis.
  • Combination therapy targeting ASC-like CAFs and immune checkpoints offers a promising strategy for pancreatic cancer treatment.

Related Concept Videos